Database : MEDLINE
Search on : Caroli and Disease [Words]
References found : 1237 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 124 go to page                         

  1 / 1237 MEDLINE  
              next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 26157755
[Au] Autor:Gu DH; Park MS; Jung CH; Yoo YJ; Cho JY; Lee YH; Seo YS; Yim HJ; Um SH; Ryu HS
[Ad] Address:Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea....
[Ti] Title:Caroli's disease misdiagnosed as intraductal papillary neoplasm of the bile duct.
[So] Source:Clin Mol Hepatol;21(2):175-9, 2015 Jun.
[Is] ISSN:2287-285X
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:Caroli's disease is a rare autosomal-recessive disorder caused by malformation of the ductal plate during embryonic development. Although it is present at birth, Caroli's disease is typically not diagnosed until between the second and fourth decades of life, as it was in the present patient. Here we report a rare case of Caroli's disease limited to one liver segment, which was initially misdiagnosed as an intraductal papillary neoplasm of the bile duct. The asymptomatic patient was treated with liver segmentectomy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1507
[Cu] Class update date: 150711
[Lr] Last revision date:150711
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3350/cmh.2015.21.2.175

  2 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25437302
[Au] Autor:Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB; Alzheimer's Disease Neuroimaging Initiative
[Ad] Address:*Medical Imaging Unit, Biomedical Engineering Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo †Laboratory of Epidemiology and Neuroimaging, IRCCS Fatebenefratelli, Brescia §Department of Decision Science, Bocconi University, Milan, Italy ‡Department of Engineering, University of Cambridge **Institute of Brain, Behaviour, and Mental Health University of Cambridge, Cambridge ∥Banner Alzheimer's Institute, Phoenix, AZ ¶Helen Wills Neuroscience Institute, University of California, Berkeley, CA #Hannover Medical School, Clinic for Nuclear Medicine, Hannover, Germany ††Departments of Internal Medicine and Psychiatry, University Hospitals and University of Geneva, Geneva, Switzerland.
[Ti] Title:Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
[So] Source:Alzheimer Dis Assoc Disord;29(2):101-9, 2015 Apr-Jun.
[Is] ISSN:1546-4156
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). METHODS: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aß1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. RESULTS: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. CONCLUSION: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Em] Entry month:1505
[Cu] Class update date: 150521
[Lr] Last revision date:150521
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1097/WAD.0000000000000071

  3 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25409057
[Au] Autor:Olano C; Mönkemüller K
[Ad] Address:Basil I. Hirschowitz Endoscopic Center of Excellence, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Alabama, USA.
[Ti] Title:Novel ERCP technique using a pushing catheter as a "mini-overtube" to remove a migrated metal stent from the bile duct.
[So] Source:Endoscopy;46 Suppl 1 UCTN:E534-5, 2014.
[Is] ISSN:1438-8812
[Cp] Country of publication:Germany
[La] Language:eng
[Mh] MeSH terms primary: Cholangiopancreatography, Endoscopic Retrograde/methods
Device Removal/methods
Lithiasis/therapy
Liver Diseases/therapy
Prosthesis Failure
[Mh] MeSH terms secundary: Bile Ducts
Caroli Disease/complications
Caroli Disease/therapy
Cholangiopancreatography, Endoscopic Retrograde/instrumentation
Cholangitis, Sclerosing/complications
Cholangitis, Sclerosing/therapy
Device Removal/instrumentation
Female
Humans
Lithiasis/complications
Liver Diseases/complications
Middle Aged
Stents/adverse effects
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1507
[Js] Journal subset:IM
[Da] Date of entry for processing:141121
[St] Status:MEDLINE
[do] DOI:10.1055/s-0034-1377637

  4 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 24621061
[Au] Autor:Mezzelani A; Landini M; Facchiano F; Raggi ME; Villa L; Molteni M; De Santis B; Brera C; Caroli AM; Milanesi L; Marabotti A
[Ti] Title:Environment, dysbiosis, immunity and sex-specific susceptibility: a translational hypothesis for regressive autism pathogenesis.
[So] Source:Nutr Neurosci;18(4):145-61, 2015 May.
[Is] ISSN:1476-8305
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Autism is an increasing neurodevelopmental disease that appears by 3 years of age, has genetic and/or environmental etiology, and often shows comorbid situations, such as gastrointestinal (GI) disorders. Autism has also a striking sex-bias, not fully genetically explainable. OBJECTIVE: Our goal was to explain how and in which predisposing conditions some compounds can impair neurodevelopment, why this occurs in the first years of age, and, primarily, why more in males than females. METHODS: We reviewed articles regarding the genetic and environmental etiology of autism and toxins effects on animal models selected from PubMed and databases about autism and toxicology. DISCUSSION: Our hypothesis proposes that in the first year of life, the decreasing of maternal immune protection and child immune-system immaturity create an immune vulnerability to infection diseases that, especially if treated with antibiotics, could facilitate dysbiosis and GI disorders. This condition triggers a vicious circle between immune system impairment and increasing dysbiosis that leads to leaky gut and neurochemical compounds and/or neurotoxic xenobiotics production and absorption. This alteration affects the 'gut-brain axis' communication that connects gut with central nervous system via immune system. Thus, metabolic pathways impaired in autistic children can be affected by genetic alterations or by environment-xenobiotics interference. In addition, in animal models many xenobiotics exert their neurotoxicity in a sex-dependent manner. CONCLUSIONS: We integrate fragmented and multi-disciplinary information in a unique hypothesis and first disclose a possible environmental origin for the imbalance of male:female distribution of autism, reinforcing the idea that exogenous factors are related to the recent rise of this disease.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1504
[Cu] Class update date: 150711
[Lr] Last revision date:150711
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1179/1476830513Y.0000000108

  5 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25966425
[Au] Autor:Plentz RR; Malek NP
[Ad] Address:Department of Internal Medicine I, Medical University Hospital, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Electronic address: Ruben.Plentz@med.uni-tuebingen.de.
[Ti] Title:Clinical presentation, risk factors and staging systems of cholangiocarcinoma.
[So] Source:Best Pract Res Clin Gastroenterol;29(2):245-52, 2015 Apr.
[Is] ISSN:1532-1916
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Cholangiocarcinoma (CCA) is the second most common primary liver tumour. Intra-hepatic CCA develops within the liver parenchyma while extrahepatic CCA involves the biliary tree within the hepatoduodenal ligament. Hilar CCA are also called Klatskin tumour. The CCA incidence has increased worldwide over the last years, but there are also geographic differences, with focus in Asian countries. Known risk factors are primary sclerosing cholangitis (PSC), hepatolithiasis, Caroli's disease, hepatitis B and C infection, liver flukes, cirrhosis, diabetes, obesity, alcohol consumption and probably tobacco smoking. Patients with early CCA have only little discomfort, but can later show episodes with jaundice and other non-specific tumour symptoms. For the staging of the disease different classifications are available, which consider various factors like tumour size, location, regional lymph nodes, metastasis, vascular involvement and tumour marker.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1505
[Js] Journal subset:IM
[St] Status:In-Process

  6 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24730630
[Au] Autor:Viswanathan S; Kumar D
[Ad] Address:Department of Pediatrics, Rainbow Babies and Children's Hospital, University Hospitals, Cleveland, Ohio, USA.
[Ti] Title:Diagnostic challenge of large congenital liver cyst in the newborn.
[So] Source:Pediatr Int;56(2):267-70, 2014 Apr.
[Is] ISSN:1442-200X
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:Liver cysts in the newborn often pose significant diagnostic challenges. Described herein is a case of large congenital liver cyst that was difficult to diagnose both antenatally and postnatally and which was later diagnosed as Caroli disease.
[Mh] MeSH terms primary: Caroli Disease/diagnosis
Cysts/diagnosis
Liver Diseases/diagnosis
[Mh] MeSH terms secundary: Cysts/congenital
Diagnosis, Differential
Female
Humans
Infant, Newborn
Liver Diseases/congenital
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1507
[Js] Journal subset:IM
[Da] Date of entry for processing:140415
[St] Status:MEDLINE
[do] DOI:10.1111/ped.12260

  7 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 26034365
[Au] Autor:Lai YH; Duan WD; Yu Q; Ye S; Xiao NJ; Zhang DX; Huang ZQ; Yang ZY; Dong JH
[Ad] Address:Yan-Hua Lai, Wei-Dong Duan, Qiang Yu, Sheng Ye, Nian-Jun Xiao, Dong-Xin Zhang, Zhi-Qiang Huang, Jia-Hong Dong, Hospital and Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China....
[Ti] Title:Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.
[So] Source:World J Gastroenterol;21(20):6296-303, 2015 May 28.
[Is] ISSN:2219-2840
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIM: To evaluate the outcomes of patients with end-stage biliary disease (ESBD) who underwent liver transplantation, to define the concept of ESBD, the criteria for patient selection and the optimal operation for decision-making. METHODS: Between June 2002 and June 2014, 43 patients with ESBD from two Chinese organ transplantation centres were evaluated for liver transplantation. The causes of liver disease were primary biliary cirrhosis (n = 8), cholelithiasis (n = 8), congenital biliary atresia (n = 2), graft-related cholangiopathy (n = 18), Caroli's disease (n = 2), iatrogenic bile duct injury (n = 2), primary sclerosing cholangitis (n = 1), intrahepatic bile duct paucity (n = 1) and Alagille's syndrome (n = 1). The patients with ESBD were compared with an end-stage liver disease (ESLD) case control group during the same period, and the potential prognostic values of multiple demographic and clinical variables were assessed. The examined variables included recipient age, sex, pre-transplant clinical status, pre-transplant laboratory values, operation condition and postoperative complications, as well as patient and allograft survival rates. Survival analysis was performed using Kaplan-Meier curves, and the rates were compared using log-rank tests. All variables identified by univariate analysis with P values < 0.100 were subjected to multivariate analysis. A Cox proportional hazard regression model was used to determine the effect of the study variables on outcomes in the study group. RESULTS: Patients in the ESBD group had lower model for end-stage liver disease (MELD)/paediatric end-stage liver disease (PELD) scores and a higher frequency of previous abdominal surgery compared to patients in the ESLD group (19.2 ± 6.6 vs 22.0 ± 6.5, P = 0.023 and 1.8 ± 1.3 vs 0.1 ± 0.2, P = 0.000). Moreover, the operation time and the time spent in intensive care were significantly higher in the ESBD group than in the ESLD group (527.4 ± 98.8 vs 443.0 ± 101.0, P = 0.000, and 12.74 ± 6.6 vs 10.0 ± 7.5, P = 0.000). The patient survival rate in the ESBD group was not significantly different from that of the ESBD group at 1, 3 and 5 years (ESBD: 90.7%, 88.4%, 79.4% vs ESLD: 84.9%, 80.92%, 79.0%, χ(2) = 0.194, P = 0.660). The graft-survival rates were also similar between the two groups at 1, 3 and 5 years (ESBD: 90.7%, 85.2%, 72.7% vs ESLD: 84.9%, 81.0%, 77.5%, χ(2) = 0.003, P = 0.958). Univariate analysis identified MELD/PELD score (HR = 1.213, 95%CI: 1.081-1.362, P = 0.001) and bleeding volume (HR = 0.103, 95%CI: 0.020-0.538, P = 0.007) as significant factors affecting the outcomes of patients in the ESBD group. However, multivariate analysis revealed that MELD/PELD score (HR = 1.132, 95%CI: 1.005-1.275, P = 0.041) was the only negative factor that was associated with short survival time. CONCLUSION: MELD/PELD criteria do not adequately measure the clinical characteristics and staging of ESBD. The allocation system based on MELD/PELD criteria should be re-evaluated for patients with ESBD.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1506
[Cu] Class update date: 150604
[Lr] Last revision date:150604
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3748/wjg.v21.i20.6296

  8 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24964219
[Au] Autor:Wang L; Larkins N; Jung B; Au NH; Mammen C
[Ad] Address:Department of Pathology and Laboratory Medicine, Children's and Women's Health Centre of British Columbia, University of British Columbia, Vancouver, BC, Canada. li.wang@cw.bc.ca.
[Ti] Title:Acute encephalopathy in a kidney transplant recipient following infusion of intravenous immunoglobulin.
[So] Source:Transpl Int;27(11):e115-7, 2014 Nov.
[Is] ISSN:1432-2277
[Cp] Country of publication:England
[La] Language:eng
[Mh] MeSH terms primary: Brain Diseases/etiology
Immunoglobulins, Intravenous/adverse effects
Kidney Transplantation/adverse effects
[Mh] MeSH terms secundary: Acute Disease
Adolescent
Caroli Disease/complications
Caroli Disease/surgery
Graft Rejection/therapy
Humans
Immunoglobulins, Intravenous/administration & dosage
Male
Polycystic Kidney, Autosomal Recessive/complications
Polycystic Kidney, Autosomal Recessive/surgery
Transplant Recipients
[Pt] Publication type:CASE REPORTS; LETTER
[Nm] Name of substance:0 (Immunoglobulins, Intravenous)
[Em] Entry month:1506
[Js] Journal subset:IM
[Da] Date of entry for processing:141020
[St] Status:MEDLINE
[do] DOI:10.1111/tri.12384

  9 / 1237 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25115876
[Au] Autor:Chandar J; Garcia J; Jorge L; Tekin A
[Ad] Address:Department of Pediatrics, Division of Pediatric Nephrology, Holtz Children's Hospital, University of Miami Miller School of Medicine, PO Box 016960 (M-714), Miami, FL, 33101, USA, jchanda2@med.miami.edu.
[Ti] Title:Transplantation in autosomal recessive polycystic kidney disease: liver and/or kidney?
[So] Source:Pediatr Nephrol;30(8):1233-42, 2015 Aug.
[Is] ISSN:1432-198X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Autosomal recessive polycystic kidney disease (ARPKD) is characterized by enlarged kidneys with dilated collecting ducts and congenital hepatic fibrosis. There is a variable rate of progression of kidney and liver disease. Portal hypertension and Caroli's disease occur from liver involvement that contributes to morbidity and mortality. Approximately 40 % of patients have a severe disease phenotype leading to rapid onset of end-stage kidney disease (ESKD) and signs of portal hypertension and the rest may have predominant involvement of either the kidney or liver. It is important for the physician to establish the extent of organ involvement before deciding on the ultimate plan of management, especially when transplantation is required. Isolated renal transplantation can be considered when liver involvement is minimal. If hepatobiliary disease is prominent, and kidney function is preserved, management options are based on individual characteristics. In the presence of significant liver disease and ESKD, consideration should be given to combined liver kidney transplantation, which can be beneficial in eliminating the consequences of both kidney and liver disease. However, this is a complex surgical procedure that needs to be performed at experienced transplant centers. Improvement in surgical techniques has considerably improved short-term graft survival with the added advantage of the liver offering immunologic protection to the kidney allograft.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1506
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1007/s00467-014-2887-3

  10 / 1237 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25808631
[Au] Autor:De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
[Ad] Address:Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli 40, 47014, Meldola, Italy, ugo.degiorgi@irst.emr.it.
[Ti] Title:(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
[So] Source:Eur J Nucl Med Mol Imaging;42(8):1276-83, 2015 Jul.
[Is] ISSN:1619-7089
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:PURPOSE: We investigated the role of (18)F-methylcholine (FCH) PET/CT in the early evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide. METHODS: The study group comprised 36 patients with a median age of 72 years (range 48-90 years) who were treated with enzalutamide 160 mg once daily after at least one chemotherapeutic regimen with docetaxel. Patients were evaluated monthly for serological prostate-specific antigen (PSA) response. FCH PET/CT was performed at baseline and repeated after 3-6 weeks. Univariate and multivariate Cox regression models addressed potential predictors of progression-free survival (PFS) and overall survival (OS). RESULTS: At a median follow-up of 24.2 months (range 1.8-27.3 months), 34 patients were evaluable for early FCH PET/CT evaluation of response, and of these 17 showed progressive disease (PD) and 17 had stable disease or a partial response. A decrease in PSA level of more than 50 % was observed in 21 patients. Early FCH PET/CT PD predicted radiological PD 3 months in advance of CT in 12 of 18 patients (66 %) and was discordant with the decrease in PSA level in 13 patients. In 6 of these, biochemical PD was confirmed in 2 months. In multivariate analysis, only decrease in PSA level and FCH PET/CT were significant predictors of PFS (p = 0.0005 and p = 0.029, respectively), whereas decrease in PSA level alone was predictive of OS (p = 0.007). CONCLUSION: This is one of the first studies to evaluate the role of FCH PET/CT as an early predictor of outcome in mCRPC patients treated with enzalutamide. Our preliminary results suggest that the combination of FCH PET/CT and decrease in PSA level could be a valid tool to predict PFS in mCRPC patients. PSA remains the single most important prognostic factor, while FCH PET/CT does not add more information on OS beyond that obtained from PSA. Further studies in larger populations are needed to confirm these data and to clarify the role of FCH PET/CT in predicting response to enzalutamide in mCRPC patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1506
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1007/s00259-015-3042-5


page 1 of 124 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information